SML0120
哌克昔林 马来酸盐
≥98% (HPLC), CPT-1 inhibitor, powder
别名:
2-(2,2-二环己基乙基)哌啶
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C19H35N · C4H4O4
化学文摘社编号:
分子量:
393.56
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
229-775-5
MDL number:
产品名称
哌克昔林 马来酸盐, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO: ≥5 mg/mL
storage temp.
2-8°C
SMILES string
OC(=O)\C=C/C(O)=O.C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
InChI
1S/C19H35N.C4H4O4/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18;5-3(6)1-2-4(7)8/h16-20H,1-15H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
InChI key
JDZOTSLZMQDFLG-BTJKTKAUSA-N
Gene Information
human ... CPT1B(1375), CPT2(1376), MTOR(2475)
General description
马来酸哌克昔林可调节冠状血管舒张并阻止运动性心动过速。它可用于治疗心绞痛和变异型心绞痛。马来酸哌克昔林是一种心脏代谢剂。它与周围神经病变、颅内高压伴乳头水肿和近端肌病有关。
Application
马来酸哌克昔林已用于阻止脂肪酸氧化。它也被用作5′腺苷单磷酸活化蛋白激酶(AMPK)激活剂和蠕虫寿命试验。
马来酸哌克昔林用作蠕虫寿命试验的原料。它还用于阻止脂肪酸氧化。
Biochem/physiol Actions
抗心绞痛代谢调节剂；肉毒碱棕榈酰转移酶抑制剂
马来酸哌克昔林是一种抗心绞痛代谢调节剂。它能够抑制线粒体酶肉毒碱棕榈酰转移酶CPT-1并在较小程度上抑制CPT-2。这导致心肌底物利用从长链脂肪酸转变为碳水化合物，从而使葡萄糖和乳酸利用率增加，并且通过与之前相同的O2消耗而增加ATP产生，从而提高心肌效率。最近还发现马来酸哌克昔林能够抑制mTORC1的活性。
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
B D Walker et al.
British journal of pharmacology, 127(1), 243-251 (1999-06-16)
Perhexiline has been used as an anti-anginal agent for over 25 years, and is known to cause QT prolongation and torsades de pointes. We hypothesized that the cellular basis for these effects was blockade of I(Kr). A stable transfection of
M A Mariscal et al.
Biochemical pharmacology, 37(18), 3461-3465 (1988-09-15)
The effect of the antianginal agent perhexiline maleate (160 mg/kg i.g., daily for 4 days) on the biliary excretion of sulfobromophthalein (BSP) and BSP-glutathione and the hepatic activity of glutathione S-transferases was investigated in Wistar rats. Perhexiline maleate caused a
B J Foster et al.
Cancer chemotherapy and pharmacology, 22(2), 147-152 (1988-01-01)
The clinical utility of adriamycin in the treatment of patients with metastatic breast cancer is often-limited by the development of drug resistance. It has been recognized that in addition to the development of primary resistance against adriamycin, malignant cells can
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0120-10MG | 04061837076909 |
| SML0120-50MG | 04061833221839 |